Skip to Content

Refludan

Active Substance: lepirudin
Common Name: lepirudin
ATC Code: B01AE02
Marketing Authorisation Holder: Celgene Europe Ltd.
Active Substance: lepirudin
Status: Withdrawn
Authorisation Date: 1997-03-13
Therapeutic Area: Thromboembolism Thrombocytopenia
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Anticoagulation in adult patients with heparin-induced thrombocytopenia type II and thromboembolic disease mandating parenteral antithrombotic therapy.

The diagnosis should be confirmed by the heparin-induced platelet activation assay or an equivalent test.

The marketing authorisation for Refludan has been withdrawn at the request of the marketing-authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide